89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022

SAN FRANCISCO , June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data in non-alcoholic steatohepatitis (NASH) will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, to be held in London, UK on June 22-26, 2022 . Presentation details are as follows: Abstract Title : Pegozafermin Led to Improved Liver Histology, Liver-related Non-invasive Tests and Metabolic Profile, With Favorable Safety and Tolerability, in an Open-label Cohort of a Phase 1b/2a Study in Subjects With Non-alcoholic Steatohepatitis Abstract Number : 3535 Format : Poster presentation (#SAT-139) Presenting Author : Rohit Loomba , MD, MHSc, Director, NAFLD Research Center , University of California San Diego Presentation Date and Time : Saturday, June 25 th 9:00 – 18:30 BST Abstract Title : Pegozafermin Led to Significant Metabolic Benefits, in Addition to Robust Beneficial Effects on the Liver, in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis (NASH) Abstract Number : 3654 Format : Poster presentation (#SAT-143) Presenting Author : Naim Alkhouri , MD, Chief of Transplant Hepatology and Director of the Fatty Liver Program, Arizona Liver Health (ALH) Presentation Date and Time : Saturday, June 25 th 9:00 – 18:30 BST Abstract Title : Pharmacokinetics (PK) and Pharmacodynamics (PD) of BIO89-100, a Novel GlycoPEGylated FGF21, in Nonalcoholic Steatohepatitis (NASH) Patients with Compensated Cirrhosis Abstract Number : 1520 Format : Poster presentation (#SAT-131) Presenting Author : Naim Alkhouri , MD, Chief of Transplant Hepatology and Director of the Fatty Liver Program, Arizona Liver Health (ALH) Presentation Date and Time : Saturday, June 25 th 9:00 – 18:30 BST About 89bio 89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco with operations in Herzliya, Israel . For more information, visit www.89bio.com or follow the company on LinkedIn . Investor Contact: Ryan Martins Chief Financial Officer [email protected] Source: 89bio, Inc. A member of the Roche Group [email protected] 655 Montgomery Street, Suite 1500 San Francisco, CA 94111, US Home Home About About Us Our Focus Our Focus Pipeline Pipeline IR Nav Media Archive LinkedIn icon © 2026 | 89bio, Inc. All rights reserved. Trademarks are property of 89bio, Inc. | Terms of Use | Privacy Statement var s_CCSWebHostingAccount = "trcg89bio"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/8191","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb107131\/themes\/site\/nir_pid3511"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNUdFuQyEI_aHmmmbZ9xBU1rqrcAN0W_9-Xl3SdtmyxQc5eORwgIsCMtarl2SB79GCWSJBxQun84H_JG4qedAiGoVa4g3sQUnC9phykRpRRzKtlIuLQkbvJ1aycAuXFxV24inQUFfywYRYJa1h9GIOil741BV6wTOq_4tuMER-4TZCBqUkrXX9_kH4vvalemm9dQyPcLxueJpO92DBV_wAzBlSRTPASur2Ay8Nqw525dStMNMc0Vby0_PxGOSNVEueDb9TtOIELH0VNDfzLbd83QfrnqmFff6fqULHDA","theme":"nir_pid3511","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"0a01461807975b1831e58f170bd7d5e5af9fce1f10b74122e7c25f8a08da69ae"}}

The release as fetched from its publisher. 89bio.com ↗